Johnson & Johnson's (JNJ) Wins $1.67B Patent Verdict Versus Abbott Laboratories (ABT)
More News related to ABT
- President of Tanzania and the Abbott Fund Dedicate Modern Emergency Medical Department
- Abbott Saving 1 Billion Gallons of Water Annually
- Abbott Completes Acquisition of Evalve, Inc.
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Impax Laboratories (IPXL) Initiates Challenges to Abbott's Patents in Connection to TRICOR
More News related to JNJ
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Johnson & Johnson (JNJ) Sets Massive Restructuring, Cutting Up to 8,000 Jobs
- J&J (JNJ) Announces Restructuring Initiatives: to 6-7% of Global Workforce, Sees Pre-Tax Savings of $1.4-$1.7B in '11
- Johnson & Johnson (JNJ) to cut 6-7% of global workforce
- Johnson & Johnson Announces Restructuring Initiatives for Sustainable Growth
Centocor Ortho Biotech Inc., wholly-owned subsidiary of Johnson & Johnson (NYSE: JNJ), announced that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories (NYSE: ABT) in a patent infringement suit.
The patent in question relates to the company's anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee.
Related Categories
Corporate NewsHot List
Stocks Mentioned
-0.09
+0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
